ADC Bio Invests $11 Million on Bioconjugation Facility

Published on: 

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and Management-10-04-2017, Volume 12, Issue 10

ADC Bio announces plans to expand into clinical and commercial drug manufacturing for ADCs.

ADC Biotechnology, a specialist antibody drug conjugates (ADCs) contract services company, announced that the company has secured investment for the construction of an $11-million bioconjugation facility in Deeside, UK, as reported in a Sept. 25, 2017 press release.

The 6500-sq.-m. facility, scheduled to be operational by December 2018, will support manufacturing in clinical phases and small-scale commercial production of ADCs. GMP production suites will be equipped with vessels of up to a few hundred liters for batch sizes up to a kilo.

In a press statement announcing the investment, the company noted that this expansion into clinical and commercial ADC is supported by the company’s Lock-Release technology. This aggregation control platform helps overcome aggregation challenges from complex, potent, and hydrophobic payloads. The technology immobilizes protein elements, keeping them separated up to the point they are conjugated, resulting in cleaner drug products and that the quality and yield of highly aggregated systems are managed in one step, the company reports.

In half of the facility footprint, the company will provide R&D technical services, quality control, quality assurance, warehousing, and process development through to manufacturing; the additional facility capacity will allow the company to upscale from early clinical phases into late phase and commercial manufacturing within the same footprint at the new facility.


Subsequent phases are planned for 2018 onwards will add further capacity for large scale clinical and commercial, and potentially, dosage form production (fill/finish).

Source: ADC Biotechnology